Hezkue (Sildenafil)

Hezkue is prescribed for conditions where improved blood flow can aid physiological function, particularly in the vascular system. Its primary clinical applications are:

• Treatment of erectile dysfunction in adult males.
• Management of pulmonary arterial hypertension to improve exercise capacity.
• Adjunct therapy for certain cases of secondary erectile impairment.
• Off‑label investigation in selected cardiovascular research protocols.
• Use in combination with lifestyle modifications for patients with mild erectile symptoms.
• Consideration as part of a comprehensive treatment plan for patients with heart failure‑related pulmonary hypertension.

• Hezkue’s active ingredient, sildenafil, selectively inhibits the enzyme phosphodiesterase type 5 (PDE5). By blocking PDE5, the drug prevents the breakdown of cyclic guanosine monophosphate (cGMP), leading to elevated intracellular cGMP levels. The increased cGMP promotes relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature, thereby enhancing blood flow to these areas and facilitating the physiological response required for erection or improved pulmonary circulation.

Adverse reactions to Hezkue may vary in frequency and severity; patients should be aware of both common and rare events that have been reported in clinical use.

Common

• Headache, often mild and transient.
• Facial flushing or warmth sensation.
• Nasal congestion or runny nose.
• Indigestion or upset stomach.
• Dizziness or light‑headed feeling.

Serious

• Sudden, unexplained loss of vision (non‑arteritic anterior ischemic optic neuropathy).
• Sudden, unexplained loss of hearing, occasionally reported.
• Priapism, a painful erection potentially lasting more than four hours.

Before starting Hezkue, certain health factors and conditions should be evaluated to minimize risk.

• Cardiovascular disease, especially recent myocardial infarction or unstable angina.
• Use of nitrate medications, which can cause severe hypotension.
• Severe liver or kidney impairment may affect drug clearance.
• Known hypersensitivity to sildenafil or any tablet components.
• Concomitant use of certain alpha‑blockers requiring dose adjustment.
• History of non‑arteritic anterior ischemic optic neuropathy.
• Retinitis pigmentosa or other retinal disorders.

Hezkue can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Nitrate drugs (e.g., nitroglycerin, isosorbide) – risk of dangerous blood pressure drop.
• Guanylate cyclase stimulators (e.g., riociguat) – additive vasodilatory effect.
• Certain potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase sildenafil levels.

Use with caution

• Alpha‑blockers (e.g., doxazosin) – monitor blood pressure.
• Antihypertensive agents – possible additive hypotensive effect.
• Other PDE5 inhibitors – avoid concurrent use.
• Grapefruit juice – may raise drug concentration modestly.